Background: Despite being commercially available for a few years now, the literature regarding the outcome of UltraflexTM stent insertion in complex malignant airway stenoses is sparse. Objectives: To assess long-term complications and survival in patients with complex malignant airway stenoses treated with insertion of nitinol stents. Methods: 60 consecutive patients with UltraflexTM stent insertion for malignant airway stenoses were included. Follow-up was obtained in all patients. Results: 62 UltraflexTM stents (covered = 51, uncovered = 11) were implanted in 60 patients. Diagnoses were bronchial carcinoma (n = 50), esophageal carcinoma (n = 3) and metastases (n = 7). Stents were inserted in the trachea (n = 5), main bronchi/intermediate bronchus (n = 22), from main bronchi/intermediate bronchus to lobar bronchi (n = 28) or in the lobar bronchi themselves (n = 7). Successful reopening of the stenoses and relief were achieved in all patients. There was no procedure-related mortality. Complications included mucous plugging in 8%, stenosing granulation tissue in 5%, tumor ingrowth in 5% and stent migration in 5% of patients. Using Kaplan-Meier estimates, the overall mean survival was 160 days (standard error: 30). Median survival was 91 days. The overall 3- and 6-month survival were 52 and 20%, respectively. Death (n = 59, 98%) was attributed mainly to disease progression with cachexia and metastases, pneumonia (n = 5, 10%), and hemoptysis (n = 1, 2%). Conclusion: UltraflexTM stents have a low complication rate and can be effectively used in complex malignant airway stenoseswith marked asymmetry or irregularity, angulation or changing diameters.

1.
Bolliger CT, Mathur PN, Beamis JF, Becker HD, Cavaliere S, Colt H, Diaz-Jimenez JP, Dumon JF, Edell E, Kovitz KL, Macha HN, Mehta AC, Marel M, Noppen M, Strausz J, Sutedja TG: ERS/ATS statement on interventional pulmonology. European Respiratory Society/American Thoracic Society. Eur Respir J 2002;19:356–373.
2.
Ernst A, Silvestri GA, Johnstone D: Interventional pulmonary procedures: guidelines from the American College of Chest Physicians. Chest 2003;123:1693–1717.
3.
Dumon JF: A dedicated tracheobronchial stent. Chest 1990;97:328–332.
4.
Dumon JF, Cavaliere S, Diaz-Jimenez JP, Vergnon JM, Venuta F, Dumon MC, Kovitz K: Seven-year experience with Dumon prosthesis. J Bronchol 1996;3:6–10.
5.
Martinez-Ballarin JI, Diaz-Jimenez JP, Castro MJ, Moya JA: Silicone stents in the management of benign tracheobronchial stenoses. Tolerance and early results in 63 patients. Chest 1996;109:626–629.
6.
Bolliger CT, Probst R, Tschopp K, Soler M, Perruchoud AP: Silicone stents in the management of inoperable tracheobronchial stenoses. Indications and limitations. Chest 1993;104:1653–1659.
7.
Freitag L, Tekolf E, Stamatis G, Greschuchna D: Clinical evaluation of a new bifurcated dynamic airway stent: a 5-year experience with 135 patients. Thorac Cardiovasc Surg 1997;45:6–12.
8.
Monnier P, Mudry A, Stanzel F, Haeussinger K, Heitz M, Probst R, Bolliger CT: The use of the covered wallstent for the palliative treatment of inoperable tracheobronchial cancers. A prospective, multicenter study. Chest 1996;110:1161–1168.
9.
Bolliger CT, Heitz M, Hauser R, Probst R, Perruchoud AP: An airway wallstent for the treatment of tracheobronchial malignancies. Thorax 1996;51:1127–1129.
10.
Saad CP, Murthy S, Krizmanich G, Mehta AC: Self-expandable metallic airway stents and flexible bronchoscopy: long-term outcomes analysis. Chest 2003;124:1993–1999.
11.
Vinograd I, Klin B, Brosh T, Weinberg M, Flomenblit Y, Nevo Z: A new intratracheal stent made from nitinol, an alloy with ‘shape memory effect’. J Thorac Cardiovasc Surg 1994;107:1255–1261.
12.
Miyazawa T, Yamakido M, Ikeda S, Furukawa K, Takiguchi Y, Tada H, Shirakusa T: Implantation of ultraflex nitinol stents in malignant tracheobronchial stenoses. Chest 2000;118:959–965.
13.
Herth F, Becker HD, LoCicero J 3rd, Thurer R, Ernst A: Successful bronchoscopic placement of tracheobronchial stents without fluoroscopy. Chest 2001;119:1910–1912.
14.
Chhajed PN, Malouf MA, Tamm M, Glanville AR: Ultraflex stents for the management of airway complications in lung transplant recipients. Respirology 2003;8:59–64.
15.
Duerig TW, Pelton AR, Stockel D: The utility of superelasticity in medicine. Biomed Mater Eng 1996;6:255–266.
16.
Stoeckel D, Pelton A, Duerig T: Self-expanding nitinol stents: material and design considerations. Eur Radiol 2004;14:292–301.
17.
Chhajed PN, Brutsche M, Tamm M: Balloon dilatation using flexible bronchoscopy for the management of benign and malignant airway stenoses. Chest 2004;125:354–355.
18.
Madden BP, Datta S, Charokopos N: Experience with ultraflex expandable metallic stents in the management of endobronchial pathology. Ann Thorac Surg 2002;73:938–944.
19.
Madden BP, Park JE, Sheth A: Medium-term follow-up after deployment of ultraflex expandable metallic stents to manage endobronchial pathology. Ann Thorac Surg 2004;78:1898–1902.
20.
Husain SA, Finch D, Ahmed M, Morgan A, Hetzel MR: Long-term follow-up of ultraflex metallic stents in benign and malignant central airway obstruction. Ann Thorac Surg 2007;83:1251–1256.
21.
Lunn W, Feller-Kopman D, Wahidi M, Ashiku S, Thurer R, Ernst A: Endoscopic removal of metallic airway stents. Chest 2005;127:2106–2112.
22.
Noppen M, Stratakos G, D’Haese J, Meysman M, Vinken W: Removal of covered self-expandable metallic airway stents in benign disorders: indications, technique, and outcomes. Chest 2005;127:482–487.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.